INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 180 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2020. The put-call ratio across all filers is 1.51 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,257,272 | +28.2% | 67,814 | -23.5% | 0.00% | +100.0% |
| Q2 2023 | $981,044 | -39.6% | 88,702 | -26.7% | 0.00% | -50.0% |
| Q1 2023 | $1,624,641 | +78.0% | 120,971 | +63.9% | 0.00% | +100.0% |
| Q4 2022 | $912,931 | -99.9% | 73,802 | -38.2% | 0.00% | -66.7% |
| Q3 2022 | $1,666,230,000 | +1100.7% | 119,443 | +1088.6% | 0.00% | – |
| Q2 2022 | $138,777,000 | -59.2% | 10,049 | -52.0% | 0.00% | – |
| Q1 2022 | $340,401,000 | -61.5% | 20,922 | -61.4% | 0.00% | -100.0% |
| Q4 2021 | $883,879,000 | +347.1% | 54,259 | +307.6% | 0.00% | – |
| Q3 2021 | $197,683,000 | -24.7% | 13,312 | +1.2% | 0.00% | – |
| Q2 2021 | $262,586,000 | -69.7% | 13,149 | -64.9% | 0.00% | -100.0% |
| Q1 2021 | $865,223,000 | -77.8% | 37,488 | -76.2% | 0.00% | -85.7% |
| Q4 2020 | $3,890,201,000 | +312.9% | 157,498 | +593.1% | 0.01% | +600.0% |
| Q3 2020 | $942,096,000 | -32.7% | 22,723 | -22.2% | 0.00% | -50.0% |
| Q2 2020 | $1,400,122,000 | -43.5% | 29,224 | -25.7% | 0.00% | -60.0% |
| Q1 2020 | $2,476,469,000 | +49.1% | 39,334 | +193.4% | 0.01% | +66.7% |
| Q4 2019 | $1,661,272,000 | +79.6% | 13,406 | -3.8% | 0.00% | +50.0% |
| Q3 2019 | $924,727,000 | -41.3% | 13,935 | -29.6% | 0.00% | -33.3% |
| Q2 2019 | $1,575,963,000 | +17.1% | 19,806 | +64.6% | 0.00% | 0.0% |
| Q1 2019 | $1,345,788,000 | +70.0% | 12,031 | +53.1% | 0.00% | +50.0% |
| Q4 2018 | $791,806,000 | -31.1% | 7,856 | -13.7% | 0.00% | 0.0% |
| Q3 2018 | $1,149,876,000 | +20.1% | 9,100 | -20.3% | 0.00% | 0.0% |
| Q2 2018 | $957,497,000 | +25.6% | 11,411 | -7.9% | 0.00% | +100.0% |
| Q1 2018 | $762,171,000 | -12.3% | 12,389 | -16.7% | 0.00% | -50.0% |
| Q4 2017 | $869,231,000 | +176.2% | 14,879 | +174.4% | 0.00% | +100.0% |
| Q3 2017 | $314,751,000 | -56.9% | 5,423 | -10.1% | 0.00% | -50.0% |
| Q2 2017 | $730,657,000 | +29.1% | 6,035 | +20.6% | 0.00% | +100.0% |
| Q1 2017 | $566,179,000 | +29.8% | 5,006 | +24.7% | 0.00% | -50.0% |
| Q4 2016 | $436,338,000 | -39.3% | 4,016 | -8.1% | 0.00% | -33.3% |
| Q3 2016 | $718,929,000 | +22.9% | 4,368 | +6.5% | 0.00% | 0.0% |
| Q2 2016 | $585,131,000 | -8.1% | 4,101 | -17.3% | 0.00% | 0.0% |
| Q1 2016 | $636,697,000 | -42.9% | 4,956 | -33.6% | 0.00% | 0.0% |
| Q4 2015 | $1,114,152,000 | +30.2% | 7,460 | +44.6% | 0.00% | +50.0% |
| Q3 2015 | $855,838,000 | -19.9% | 5,160 | +16.5% | 0.00% | -33.3% |
| Q2 2015 | $1,069,072,000 | +312.5% | 4,429 | +381.9% | 0.00% | +200.0% |
| Q1 2015 | $259,177,000 | +10283.7% | 919 | +5643.8% | 0.00% | – |
| Q4 2014 | $2,496,000 | -97.9% | 16 | -96.8% | 0.00% | – |
| Q3 2014 | $118,345,000 | +2074.7% | 500 | +2073.9% | 0.00% | – |
| Q2 2014 | $5,442,000 | +14.5% | 23 | +27.8% | 0.00% | – |
| Q1 2014 | $4,754,000 | -28.2% | 18 | -81.4% | 0.00% | – |
| Q4 2013 | $6,623,000 | – | 97 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chicago Capital Management, LLC | 185,781 | $4,611,565 | 12.16% |
| Samsara BioCapital, LLC | 640,688 | $11,878,356 | 3.64% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,203,295 | $40,849,089 | 2.14% |
| Versor Investments LP | 378,480 | $7,017,019 | 1.42% |
| Magnetar Financial LLC | 2,407,209 | $44,629,655 | 1.14% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,077,893 | $38,524,136 | 0.85% |
| Fort Baker Capital Management LP | 430,600 | $7,983,324 | 0.74% |
| EHP Funds Inc. | 84,210 | $1,561,253 | 0.73% |
| Terrapin Asset Management, LLC | 30,000 | $556,200 | 0.63% |
| AQR Arbitrage LLC | 734,970 | $13,626,344 | 0.61% |